Skip to main content
SciBX: Science-Business eXchange
As published Thursday, June 13, 2013


  • Cover Story: Personalizing cystic fibrosis in vitro

    By Chris Cain, Senior Writer

    A team at University Medical Center Utrecht has developed a rapid and quantitative in vitro intestinal cell-based assay for CFTR function that could help prospectively identify responders to targeted cystic fibrosis therapies.1 The researchers are now planning to test how well the approach can predict drug responses in the clinic. 

    Cystic fibrosis is caused by inherited mutations that reduce the function of the cystic fibrosis transmembrane conductance regulator (CFTR), an anion channel that helps keep the lung and intestinal epithelium hydrated and prevents the mucus buildup that leads to airway obstruction and infection.

    Full Article

Distillery

  • This Week in Therapeutics

    Mitigating chemotherapy-induced infertility by blocking PI3K-PTEN-AKT signaling; treating osteoarthritis by disrupting TGFbeta1 signaling; alleviating neuropathic pain by inhibiting GRIN2B; and more...

  • more therapeutics news
  • This Week in Techniques

    Screening platform for detecting RAF dimerization in cells; phage display system for rapid mammalian expression of library hits; database of human phosphatase-substrate interactions; and more...

  • more techniques news
Subscribe Now
Free Trial